22 July 2020
Amsterdam, NL – The Journal of Parkinson's Diseaseand its publisher IOS Press are proud to announce the two articles that have won the first Parkinson Prize, recognizing these outstanding contributions to the advancement to Parkinson's disease research. Recipients of the award are lead investigator Thomas Foltynie, MD, PhD (research article) and co-authors Heiko Braak, MD, and Kelly Del Tredici, MD, PhD (review article).
9 July 2020
Amsterdam, NL – Timely administration of anti-Parkinson drugs is a significant issue for hospitalized patients with Parkinson's disease (PD) with late or missed doses resulting in longer stays and worse outcomes.
7 July 2020
Amsterdam, NL – The Journal of Parkinson's Disease (JPD) and its publisher IOS Press are proud to announce that JPD's Journal Impact Factor has increased to 5.178 according to Clarivate's 2020 edition of the Web of Science Journal Citation Reports™ (JCR). This represents an impressive 40% increase from last year.
4 June 2020
Growth factors such as glial cell line-derived neurotrophic factor (GDNF) were initially thought to be exciting new treatments for Parkinson’s disease, but trials have been disappointing. A panel of prominent leaders in the field convened to discuss whether there is a future for this approach and what any future PD trial involving GDNF and other GDNF family neurotrophic factors should consider. Their discussions and recommendations are published in the Journal of Parkinson's Disease.
12 May 2020
Amsterdam, NL – Parkinson's disease (PD) is expected to reach over 14 million cases worldwide by 2040. As longevity increases, so does the number of persons living with PD.
6 May 2020
Despite 30 years of research, not a single therapy has been found to successfully delay or stop the progression of Parkinson's disease. In the Journal of Parkinson's Disease scientists report on the possibility of using a multi-arm, multi-stage trial platform to evaluate several potential therapies at once, using lessons learned from other diseases.
5 May 2020
Two purines, caffeine and urate, have been associated with a reduced risk of Parkinson's disease (PD) in multiple study groups and populations. Analysis of data from the Harvard Biomarkers Study shows that lower levels of caffeine consumption and lower blood urate are inversely associated with PD, strengthening the links between caffeine intake and urate levels and PD, reports a study in JPD.
3 April 2020
Amsterdam, NL – While much attention has focused on the potential for severe respiratory complications and unfavorable outcomes from the COVID-19 pandemic among patients with Parkinson's disease (PD), the impact extends beyond these threats.
12 February 2020
Amsterdam, NL – In order to provide the best medical care for newly diagnosed Parkinson's disease (PD) patients, a method of predicting their cognitive and motor progression, beyond using purely clinical parameters, would have major implications for their management.
11 February 2020
Amsterdam, NL – To better understand the relationship between physical activity and Parkinson's disease (PD) investigators in Sweden analyzed medical records of nearly 200,000 long-distance skiers who took part in the Vasaloppet cross-country ski race.